Skip to main content

Table 3 Impact of patients’ characteristics and comorbidities on adherence and persistence to UC treatments

From: Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database

  Adherence Persistence
  Patient’s adherent over 12 months n (%) Adjusted OR [95% CI] Patient’s persistent at 12 months n (%) Adjusted OR [95% CI]
Sex     
· Male 222 (30.5) 1.3 365 (50.1) 1.4
· Female 243 (25.5) [1.05–1.6] 400 (42.0) [1.1–1.7]
Age     
· < 60 201 (23.3) 1.6 381 (44.1) NS
· ≥ 60 264 (32.3) [1.3–2.0] 384 (49.9)  
Previous use of corticosteroids     
· Yes 142 (28.2) NS 231 (45.8) NS
· No 323 (27.4)   534 (45.4)  
Concurrent use of corticosteroids     
· Yes 179 (32.7) 1.4 273 (49.8) 1.4
· No 286 (25.2) [1.1–1.8] 492 (43.4) [1.1–1.7]
Heart disease     
· Yes 210 (30.2) NS 321 (46.2) NS
· No 255 (25.9)   444 (45.0)  
Respiratory illness     
· Yes 153 (26.8) NS 247 (43.3) 1.2
· No 312 (28.1)   518 (46.6) [1.004–1.548]
Hypertension     
· Yes 262 (31.1) NS 403 (47.9) 1.2
· No 203 (24.2)   362 (43.1) [1.01–1.50]
Diabetes     
· Yes 167 (30.4) NS 515 (45.5) NS
· No 298 (26.3)   250 (45.5)  
Chronic disease score     
· Yes 159 (23.2) NS 296 (43.3) NS
· No 306 (30.7)   469 (47.0)  
  1. CI, confidence interval; NS, not significant; OR, odds ratio; UC, ulcerative colitis.